NDLI: mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Please wait, while we are loading the content...

Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Adherence to rotavirus vaccination quality measures in a commercially insured population.

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development.

An improved whole cell pertussis vaccine with reduced content of endotoxin.

Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.

A pilot study on the effects of individually tailored education for MMR vaccine-hesitant parents on MMR vaccination intention.

Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.

Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease.

Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.

Recommendations for tick-borne encephalitis vaccination from the Central European Vaccination Awareness Group (CEVAG).

A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Do the quality of the trials and the year of publication affect the efficacy of intervention to improve seasonal influenza vaccination among healthcare workers?: Results of a systematic review.

Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Autologous heat-shock protein vaccines.

Correlates of comfort with alternative settings for HPV vaccine delivery.

Phenotypic and functional analysis of the modification of murine bone marrow dendritic cells (BMDCs) induced by neutral Ginseng polysaccharides (NGP).

Bordetella pertussis infection in a child with completed primary immunization: A case report.

New generation of dendritic cell vaccines.

Development of a Vero cell DNA reference standard for residual DNA measurement in China.

Profile: transgene.

GSK's four-strain seasonal influenza vaccine approved in the US.

Letter from the editor.

Year: 2013 Volume: 9 Issue: 1

Year: 2012 Volume: 8

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Van Lint, Sandra Heirman, Carlo Thielemans, Kris Breckpot, Karine
Description	Country affiliation: Belgium Author Affiliation: Van Lint S ( Laboratory of Molecular and Cellular Therapy)
Abstract	Two decades ago, mRNA became the focus of research in molecular medicine and was proposed as an active pharmaceutical ingredient for the therapy of cancer. In this regard, mRNA has been mainly used for ex vivo modification of antigen-presenting cells (APCs), such as dendritic cells (DCs). This vaccination strategy has proven to be safe, well tolerated and capable of inducing tumor antigen-specific immune responses. Recently, the direct application of mRNA for in situ modification of APCs, hence immunization was shown to be feasible and at least as effective as DC-based immunization in pre-clinical models. It is believed that application of mRNA as an off-the-shelf vaccine represents an important step in the development of future cancer immunotherapeutic strategies. Here, we will discuss the use of ex vivo mRNA-modified DCs and 'naked mRNA' for cancer immunotherapy focusing on parameters such as the employed DC subtype, DC activation stimulus and route of immunization. In addition, we will provide an overview on the clinical trials published so far, trying to link their outcome to the aforementioned parameters.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
Journal	Human Vaccines & Immunotherapeutics
Issue Number	2
Volume Number	9
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-02-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Biological Products Metabolism Cancer Vaccines Immunology Dendritic Cells Immunotherapy Rna, Messenger Drug Discovery Neoplasms Therapy Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

DNA vaccine for cancer immunotherapy.

New generation of dendritic cell vaccines.

Engineering better immunotherapies via RNA interference.

Dendritic cell based vaccines for HIV infection: the way ahead.

Immunotherapy for melanoma: current status and perspectives.

DCVax®-L--developed by Northwest Biotherapeutics.

Clinical evaluation of therapeutic cancer vaccines.

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Similar Documents

Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

DNA vaccine for cancer immunotherapy.

New generation of dendritic cell vaccines.

Engineering better immunotherapies via RNA interference.

Dendritic cell based vaccines for HIV infection: the way ahead.

Immunotherapy for melanoma: current status and perspectives.

DCVax®-L--developed by Northwest Biotherapeutics.

Clinical evaluation of therapeutic cancer vaccines.

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.